Medici List crest

ASHLAND INC.

CIK: 16748622 Annual ReportsLatest: 2026-11-20
Revenue: N/ANet Income: $4,000,000Source 10-K
Disclaimer: AI-assisted summary of SEC Form 10-K filings. Not official company content and not investment, legal, accounting, or tax advice. See full disclaimer here.

10-K / November 20, 2026

Revenue:N/A
Income:$4,000,000

10-K / November 18, 2024

Revenue:$2,200,000,000
Income:$169,000,000

10-K / November 20, 2026

Ashland Inc.

Overview

  • Company: Global additives and specialty ingredients company with a sustainability focus.
  • Listing: NYSE ticker ASH.
  • Headquarters: Principal executive offices in Wilmington, Delaware.
  • Employees: Approximately 2,800 worldwide.
  • Global reach: Serves customers in more than 100 countries; operates in 31 countries.
  • Reportable segments: Life Sciences, Personal Care, Specialty Additives, Intermediates. Unallocated and Other covers corporate functions and legacy matters.
  • Facilities:
    • Life Sciences: 10 manufacturing facilities and 10 laboratory facilities.
    • Personal Care: 9 manufacturing and laboratory facilities across 10 countries; U.S. sites include Bridgewater Township, NJ; Freetown, MA; Kenedy, TX. International sites include Brazil, China, France, Germany, India, Mexico, Netherlands, Thailand, United Kingdom.
    • Intermediates: Manufacturing facility in Lima, Ohio; some derivatives produced at Life Sciences facilities in Texas City, TX and Calvert City, KY.
    • Avoca: Business sold in March 2025 (formerly part of Personal Care).
  • Primary markets: Architectural coatings, construction, energy, food & beverage, personal care, pharmaceutical, and other industrial markets.
  • Information security and governance: Enterprise Risk Management (ERM) program with an incident-response framework aligned to NIST Cybersecurity Framework 2.0; 24/7 Security Operations Center; risk-based third-party/vendor management; Board-level oversight via the Audit Committee.

Segment descriptions and key product areas

Life Sciences

  • Focus: Excipients, formulation technologies, tablet coating systems for pharmaceuticals; bioprocessing chemicals for biologics, vaccines, and therapeutics; nutrition thickeners/emulsifiers; agricultural chemical formulations.
  • Markets served: Pharmaceutical, nutrition, agricultural chemical, and diagnostic films.
  • Footprint: 10 manufacturing facilities and 10 laboratory facilities; global locations include Texas City, TX; Calvert City, KY; Columbus, OH; Wilmington, DE; Brazil; Belgium; China; France; Germany; India; Ireland; Mexico; Netherlands; Thailand; Turkey.
  • 2026 sales mix (top Life Sciences categories):
    • Cellulosics: 47% of Life Sciences sales; 40% of Ashland’s total consolidated sales.
    • Polyvinylpyrrolidones (PVP): 39% of Life Sciences sales; 24% of Ashland’s total consolidated sales.

Personal Care

  • Focus: Biofunctional actives, preservatives, skin care, sun care, oral care, hair care, and household solutions; natural and nature-derived ingredients; encapsulation and specialty polymers.
  • Markets served: Personal care and cleaning products.
  • Footprint: 9 manufacturing and laboratory facilities in 10 countries; U.S. sites include Bridgewater Township, NJ; Freetown, MA; Kenedy, TX. International locations include Brazil, China, France, Germany, India, Mexico, Netherlands, Thailand, United Kingdom.
  • Avoca business sold in March 2025 (previously part of Personal Care).
  • 2026 sales mix (top Personal Care categories):
    • Cellulosics: 21% of Personal Care sales; 40% of Ashland’s total consolidated sales.
    • PVP: 23% of Personal Care sales; 24% of Ashland’s total consolidated sales.

Specialty Additives

  • Focus: Rheology and performance-enhancing additives for architectural paints/coatings, construction materials, energy, automotive, and various industrial markets.
  • Capabilities: Cellulosic and synthetic thickeners, foam-control agents, surfactants/wetting agents, pH neutralizers, deposition/conditioning aids, and related rheology and dispersion technologies.
  • Customers: Global paint manufacturers, electronics and automotive manufacturers, textile operations, construction, and oilfield services.
  • Footprint: 8 manufacturing and laboratory facilities across 8 countries; U.S. facilities in Wilmington, DE and Hopewell, VA.
  • 2026 sales mix (top Specialty Additives products):
    • Cellulosics: 60% of Specialty Additives sales; 40% of Ashland’s total consolidated sales.
    • PVP: 8% of Specialty Additives sales; 24% of Ashland’s total consolidated sales.

Intermediates

  • Focus: Production of 1,4-butanediol (BDO) and related derivatives (including N‑methylpyrrolidone) used as chemical intermediates and specialty solvents.
  • Customers: Life Sciences, Personal Care, and Specialty Additives segments; general industrial manufacturers, plastics and polymers producers, pharmaceutical companies, agricultural firms, and electronics component makers.
  • Footprint: Lima, Ohio manufacturing facility; some derivatives produced at Life Sciences facilities in Texas City, TX and Calvert City, KY.
  • Markets: Americas, Europe, and Asia Pacific.

Environmental, social, and governance (ESG) and risk highlights

  • Environmental and remediation:
    • Environmental remediation reserves: $222 million as of Sept 30, 2026, with upper-end potential costs up to approximately $470 million.
    • Environmental remediation expense (net of insurance recoveries): $38 million (2026), $48 million (2025), $56 million (2024).
  • Product controls and regulatory:
    • Compliance with TSCA (U.S.), REACH (EU), CSAR (China), GHS, and other global chemical regulations; ongoing product registration and supply-chain information requirements.
    • Ongoing climate-related regulatory developments include CSRD and proposed SEC climate rules; efforts to align with a 1.5°C pathway and Science-Based Targets Initiative (SBTi) targets approved in Nov 2023.
  • Human capital:
    • Approximately 2,800 employees in 31 countries (as of Sept 30, 2026).
    • Emphasis on pay equity, living wage certification (Global Living Wage Employer by Fair Wage Network since 2024), and talent development and leadership programs.
  • Cybersecurity and information technology:
    • Enterprise-wide cybersecurity program with 24/7 SOC, threat hunting, employee training, third-party risk management, and ongoing testing and third-party assessments.
    • Board-level oversight of information and cybersecurity risks through the Audit Committee.
  • Legal and regulatory:
    • Ongoing environmental, product liability, asbestos-related, and other litigation and claims with established reserves; CERCLA/PRP sites; Passaic River matters; and other proceedings.
  • Taxation and global operations:
    • Complex global tax environment with Pillar Two minimum tax and transfer pricing considerations; potential changes to tax laws that could affect effective tax rate and cash taxes.

Key takeaways

  • Ashland is a diversified global additives and specialty ingredients company with four reportable segments and a broad international footprint.
  • Life Sciences and Specialty Additives are major contributors to sales, with heavy reliance on cellulosics and PVP across the portfolio.
  • Personal Care maintains a broad portfolio of natural and nature-derived ingredients and completed the sale of the Avoca business in March 2025.
  • The company emphasizes ESG, risk management, and cybersecurity while managing environmental remediation obligations and a complex global operating environment.